Lost your password?

Blogs about: Muscarinic

Featured Blog

Spiriva sustains lung function over 4 years

crimsoncanary wrote 1 year ago: Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial  … more →

Tags: Spiriva, tiotropium bromide

Ipratropium use linked to increased cardiovascular deaths

crimsoncanary wrote 1 year ago: Data published in teh Annals of Internal Medicine show that ipratropium may elevate risk for all-cau … more →

Tags: Antagonist, Ipratropium

GSK publish series of muscarinic antagonists

crimsoncanary wrote 1 year ago: GSK have published a series of biphenyl piperazine muscarinic acetylcholine receptor antagonists … more →

Tags: GSK, Antagonist

Almirall receive $15M milestone from Forest for aclidinium bromide

crimsoncanary wrote 1 year ago: Almirall has received a 15 million dollar payment from Forest Laboratories in connection with its ph … more →

Tags: Antagonist, forest, Licensing, phase iii, aclidinium bromide

GSK initiate Phase I trial of Muscarinic M1 antagonist GSK1034702

crimsoncanary wrote 1 year ago: GSK have initiated a Phase I trial of Muscarinic M1 antagonist GSK1034702 … more →

Tags: GPCR, GSK, Antagonist, Muscarinic M1, M1, GSK1034702

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

crimsoncanary wrote 1 year ago: Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160 … more →

Tags: GSK, Antagonist, GlaxoSmithKline, Licensing, Phase I, Theravance, lama, GSK1160724, TD-4208

Theravance annouces positive Phase II results of MABA GSK961081 in COPD

crimsoncanary wrote 1 year ago: Theravance/GSK have announced positive results from a Phase II study of GSK961081 for the treatment … more →

Tags: GPCR, agonist, GSK, Antagonist, GlaxoSmithKline, Theratechnologies, GSK961081, GSK-961081, 961081

Mithridion commences Phase I Trial of MCD-386 for Alzheimer’s Disease

crimsoncanary wrote 1 year ago: Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. … more →

Tags: Phase I, Muscarinic M1, M1, MCD-386, MCD386, Mithridion

Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling

crimsoncanary wrote 1 year ago: Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chroni … more →

Tags: Antagonist, phase iii, sciele, Muscarinic M3, M3, Glycopyrrolate, Robinul

Lillys long acting injection olanzapine shows similar profile to Zyprexa

crimsoncanary wrote 1 year ago: Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long ac … more →

Tags: GPCR, 5-HT2A, Antagonist, 5HT2A, 5HT3, 5-HT3, Dopamine, 5ht6, 5-ht6

Acadias ACP-104 does not meet endpoint in Phase IIb Schizophrenia trial

crimsoncanary wrote 1 year ago: Acadia’s ACP-104 did not meet its primary endpoint of antipsychotic efficacy in a Phase IIb Sc … more →

Tags: GPCR, 5-HT2A, agonist, 5HT2A, Dopamine D3, Dopamine D2, Dopamine, phase ii, acadia

Researchers from the Italy publish series of Pyrrolidinylfuran Muscarinic M2 agonists

crimsoncanary wrote 1 year ago: Researchers from the University of Florence, University Camerino and the Inst Sup di Sanita have pub … more →

Tags: GPCR, agonist, M2

Watsons Oxybutynin topical gel has improved skin tolerability

crimsoncanary wrote 1 year ago: Watson’s Oxybutynin topical gel has demonstrated improved skin tolerability compared to the ox … more →

Tags: GPCR, Antagonist, Watson, oxybutynin


Related Tags
All →

Follow this tag via RSS